HUTCHMED (CHINA) LIMIT

HUTCHMED Included in FTSE Russell Indexes

19 12 2021 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

13 12 2021 23:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

10 12 2021 04:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

05 12 2021 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

02 12 2021 23:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

23 11 2021 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

07 11 2021 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

31 10 2021 23:15:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

27 10 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

28 9 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

28 9 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

20 9 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

19 9 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

13 9 2021 01:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

08 9 2021 05:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

07 9 2021 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

06 9 2021 01:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

25 8 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

22 8 2021 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

08 8 2021 19:00:00 提供 Nasdaq GlobeNewswire